Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Commonalities"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
dewey-ones:"140 - Specific philosophical schools"
Showing
1
-
20
of
78
Search:
'"Commonalities"'
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Reslizumab (Cinqair)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
2
Entyvio (Vedolizumab)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
3
Tocilizumab (Actemra, intravenous) : for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have r...
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
4
Tocilizumab (Actemra) : adult patients with moderately to severely active rheumatoid arthritis
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
5
Reslizumab (Cinqair)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
6
Tocilizumab (Actemra) : adult patients with moderately to severely active rheumatoid arthritis
Published 2015
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
7
Entyvio (Vedolizumab)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...
Common
drug review...
”
Read Now
8
Clinical review report: Tocilizumab (Actemra) (Hoffmann-La Roche Limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
Read Now
9
Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
Published 2018
CADTH
“
...CADTH
common
drug review...
”
Read Now
10
Pharmacoeconomic review report: Ixekizumab (Taltz)
Published 2017
CADTH
“
...CADTH
common
drug review...
”
Read Now
11
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
Read Now
12
Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
Read Now
13
Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)
Published 2017
CADTH
“
...CADTH
common
drug review...
”
Read Now
14
Pharmacoeconomic review report: Sarilumab (Kevzara)
Published 2017
CADTH
“
...CADTH
common
drug review...
”
Read Now
15
Patient group input submissions: Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited)
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
Read Now
16
CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis
Published 2017
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
Read Now
17
Clinical review report: Tocilizumab (Actemra) (Hoffmann-La Roche Limited)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
Read Now
18
Pharmacoeconomic review report: Burosumab (Crysvita), Kyowa Kirin Limited : indication : for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
Read Now
19
Clinical review report: Brolucizumab (Beovu) (Novartis Pharmaceuticals Canada Inc.) : indication : treatment of neovascular (wet) age-related macular degeneration (AMD)
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
Read Now
20
Clinical review report: Burosumab (Crysvita) (Kyowa Kirin limited) : indication: for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
...CADTH
common
drug review...
”
1
2
3
4
Back
Narrow Search
Remove Filters
Clear Filter
Classification: 140 - Specific philosophical schools
Year of Publication
From:
To:
Classification
140 - Specific philosophical schools
330 - Economics
28
610 - Medicine & health
28
700 - The arts; fine & decorative arts
20
Language
English
78
Collection
National Center for Biotechnology Information
78
Author
Canadian Agency for Drugs and Technologies in Health
66
CADTH Canadian Drug Expert Committee
24
Multiple Sclerosis Society of Canada
1
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=dewey-ones%3A%22140+-+Specific+philosophical+schools%22&lookfor=%22Commonalities%22&type=Series
Send by Email
×
Loading...